| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9149(00)01230-3 |
| P698 | PubMed publication ID | 11113401 |
| P2093 | author name string | F Fischer | |
| H P Schultheiss | |||
| R Stern | |||
| R Agrawal | |||
| H R Arntz | |||
| W Wunderlich | |||
| L Schnitzer | |||
| P2860 | cites work | Validation of a new automatic system for biplane quantitative coronary arteriography. | Q52865713 |
| Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) | Q67514041 | ||
| Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B | Q68564239 | ||
| The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts | Q71966442 | ||
| Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) | Q72220309 | ||
| Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group | Q72741422 | ||
| Comparative in-vitro validation of eight first- and second-generation quantitative coronary angiography systems | Q73484232 | ||
| Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty | Q73746075 | ||
| EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events | Q73825436 | ||
| Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile | Q77291934 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Myocardial perfusion and regression of coronary artery disease in patients on a regimen of intensive physical exercise and low fat diet | Q39244576 | ||
| Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction | Q46304032 | ||
| Antiatherothrombotic properties of statins: implications for cardiovascular event reduction | Q48011361 | ||
| Analytic isocenter calibration. A new approach for accurate x-ray gantries | Q48534377 | ||
| Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. | Q50595888 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | artery disease | Q18965518 |
| P304 | page(s) | 1293-1298 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study) | |
| P478 | volume | 86 |
| Q34154695 | ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g |
| Q36478221 | Application of intravascular ultrasound in anti-atherosclerotic drug development |
| Q44090192 | Clinical implications of statin event trials |
| Q43718360 | Developing a clinical strategy for cholesterol management in an era of unanswered questions |
| Q34714444 | Disparity between angiographic regression and clinical event rates with hydrophobic statins |
| Q34674169 | Early use of statins in acute coronary syndromes |
| Q78871471 | Early use of statins in acute coronary syndromes |
| Q36681810 | Effect of early statin treatment in patients with cardiogenic shock complicating acute myocardial infarction |
| Q24806340 | Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696] |
| Q80675789 | Immediate effect of fluvastatin on lipid levels in acute coronary syndrome |
| Q44026877 | Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes |
| Q77122100 | Interventions in cardiology: focus on lipid management in acute and long-term settings |
| Q37210613 | Lipid management: considerations in acute coronary syndrome |
| Q37396588 | Lipid management: considerations in acute coronary syndrome |
| Q37535044 | Lipid reduction in acute coronary syndrome: how much, when, and how? |
| Q34674174 | Lipid-lowering therapies in the management of acute coronary syndromes |
| Q34682221 | Niacin for primary and secondary prevention of cardiovascular events. |
| Q35077225 | Optimizing lipid management in patients with acute coronary syndromes |
| Q42700220 | Patients with acute coronary syndrome should start a statin while still in hospital |
| Q34428169 | Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines |
| Q37237515 | Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative |
| Q44613104 | Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function |
| Q44384641 | Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. |
| Q44016826 | Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes |
| Q35955693 | Should standard medical therapy for angina include a statin? |
| Q46199534 | Should we treat all primary prevention patients with statins? |
| Q24245521 | Statins and fibrates for preventing melanoma |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q24193862 | Statins for acute coronary syndrome |
| Q24236697 | Statins for acute coronary syndrome |
| Q24243557 | Statins for acute coronary syndrome |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q35839494 | Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction |
| Q51927421 | The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol. |
| Q35674095 | The next step in cardiovascular protection |
| Q34327214 | The use of statins in acute coronary syndromes: the mechanisms behind the outcomes |
| Q76336944 | [Intervention program to improve secondary prevention of myocardial infarction. Results of the PRESENTE (early secondary prevention) study] |
Search more.